Archives

Clinical, Safety, and Quality Outcomes of a Hypertrophic Cardiomyopathy Clinical Pharmacy Management Program 216 115 Shields Health Solutions

Clinical, Safety, and Quality Outcomes of a Hypertrophic Cardiomyopathy Clinical Pharmacy Management Program

    This poster evaluates the clinical, safety, and quality outcomes of a pharmacist-led HCM clinical management program.  

Analysis of Oral Oncolytic Waste for Patients Filling at a Health System Specialty Pharmacy 216 115 Shields Health Solutions

Analysis of Oral Oncolytic Waste for Patients Filling at a Health System Specialty Pharmacy

    This poster evaluates existing oral oncology medication waste events among patients filling at a HSSP.  

Unlocking the Full Potential of Your DIY Specialty Pharmacy Program: Why Strategic Partnership Matters 70 70 Shields Health Solutions

Unlocking the Full Potential of Your DIY Specialty Pharmacy Program: Why Strategic Partnership Matters

Specialty pharmacy is one of the fastest-growing and most essential parts of today’s healthcare landscape — and you’re likely already feeling both the opportunity and the pressure. As the number…

How CHRISTUS Health Reimagined Diabetes Support Through Health System Specialty Pharmacy 70 70 Shields Health Solutions

How CHRISTUS Health Reimagined Diabetes Support Through Health System Specialty Pharmacy
This white paper explores the opportunities and unknowns that health organizations must consider when weighing the implementation of AI.
Shields Health Solutions Partners with Major Academic Medical Center to Expand Specialty Pharmacy Services 204 115 Shields Health Solutions

Shields Health Solutions Partners with Major Academic Medical Center to Expand Specialty Pharmacy Services

STOUGHTON, Mass. (May 13, 2025)–Shields Health Solutions (Shields), the premier specialty pharmacy accelerator in the country announced it has partnered with Duke Health, a leading academic health system in North…

Analysis of Glucagon-Like Peptide-1 Agonist Trends Within An Integrated Health System Specialty Pharmacy 70 70 Shields Health Solutions

Analysis of Glucagon-Like Peptide-1 Agonist Trends Within An Integrated Health System Specialty Pharmacy

  According to the CDC, approximately 38 million Americans have diabetes (about 1 in 10) and approximately 90-95% of those have type 2 diabetes. GLP-1 and GLP-1/GIP agonists are now recognized…

Addressing GLP-1 Access and Adherence Challenges with Specialty Pharmacy Solutions 70 70 Shields Health Solutions

Addressing GLP-1 Access and Adherence Challenges with Specialty Pharmacy Solutions

Whether through social media, traditional news outlets, or word of mouth, discussions about GLP-1 therapy are everywhere. These medications, originally approved by the FDA for the treatment of Type 2…

Shields Outcomes 2024 Report 70 70 Shields Health Solutions

Shields Outcomes 2024 Report
This white paper explores the opportunities and unknowns that health organizations must consider when weighing the implementation of AI.
Clinical and Quality Outcomes of a Bleeding Disorder Program in a Health System Specialty Pharmacy 216 115 Shields Health Solutions

Clinical and Quality Outcomes of a Bleeding Disorder Program in a Health System Specialty Pharmacy

This poster evaluates the clinical and quality outcomes of a bleeding disorder program at a health system HSSP.

Establishing Proportion of Days Covered Benchmarks for Health System Specialty Pharmacy Clinical Outcomes Evaluation 216 115 Shields Health Solutions

Establishing Proportion of Days Covered Benchmarks for Health System Specialty Pharmacy Clinical Outcomes Evaluation

This poster aims to establish goals for a dashboard displaying medication adherence by disease state and PDC thresholds through a comprehensive literature review, validating the existing targets.